Solstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantActivity from announced rounds
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
An enterprise gateway for AI-model access, request security, budgets and routing.
Developing transformative, best-in-class neuropsychiatric therapies
Develops next-generation therapies for migraine prevention
Builds agentic recruiting platform that screens high-volume candidates via voice, video, SMS, and resume agents
Builds shared context infrastructure for AI-native teams
Develops high-Mach unmanned aircraft for national security missions
Provides AI-powered penetration testing platform to secure environments against AI-driven cyberat...